Panax Ginseng
Panax ginseng · Asian Ginseng · Korean Red Ginseng
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
Mixed-to-moderate RCT support, downgraded from the prior 4. Three separate meta-analytic bodies each show a real but small signal that stops short of a robust effect. For fatigue, Bach et al. (Front Pharmacol 2020) pooled 8 RCTs (678 participants) and found ginseng superior to placebo on clinical effect (OR 1.31, 95% CI 1.17 to 1.46), with risk-of-bias scores of 4 to 7 out of 7 and publication bias detected on some markers. For erectile function, the Cochrane review (Lee, Lee, Kim et al. 2021; 9 RCTs, 587 men) found only a trivial effect on the IIEF-15 erectile-function domain (MD 3.52, 95% CI 1.79 to 5.25) that sits below the 4-point clinically important threshold, graded low-certainty, with most trials run in South Korea. For glycemia, Shishtar et al. (PLoS One 2014; 16 RCTs, 770 participants) found a modest fasting-glucose reduction (MD -0.31 mmol/L, 95% CI -0.59 to -0.03) but no effect on HbA1c or insulin, with severe heterogeneity (I-squared 89%) and funnel-plot asymmetry suggesting bias. The pattern of small effects, heavy South Korean/Chinese trial provenance, product heterogeneity, and publication bias caps honest confidence at 3.
- FDA
- Legal supplement (DSHEA); Korean Red Ginseng regulated as functional food in Korea
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Well tolerated for most, but a documented warfarin interaction that lowers INR, possible additive glucose-lowering, sleep disruption, and genuine product-quality variability make sourcing and clinician oversight the main risks.
Panax ginseng is the true ginseng of East Asian medicine, an adaptogenic root whose active ginsenosides (Rg1, Rb1, Re and relatives) give it a broad, diffuse pharmacology rather than one sharp effect. Korean Red Ginseng is the steamed-and-dried form, which shifts the ginsenoside profile versus white sun-dried root. Modern trials find small, real signals for fatigue, erectile function, and fasting glucose, but the effects are modest and the evidence base leans heavily on South Korean and Chinese trials with documented heterogeneity and publication bias. Sourcing is a genuine concern, since species substitution and adulteration have a long history. The honest headline is a well-studied traditional root with many small positive signals and few large, clean ones.
The "all-healing" panacea root with two millennia of Korean tradition and substantial modern clinical evidence, and substantial adulteration concerns.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Panax ginseng is the true ginseng, the Greek genus name Panax derives from panakeia ("all-healing"), and the species name ginseng from the Chinese 人参 (rén shēn, "person root") referring to the root's sometimes-anthropomorphic forking shape that has fascinated traditional medicine practitioners for millennia. The Panax genus contains multiple distinct species with different active compound profiles and clinical applications: Panax ginseng (Korean/Asian ginseng, cultivated extensively in Korea, China, and Russia), Panax quinquefolius (American ginseng, native to eastern North America with substantially different ginsenoside profile and considered "cooling" rather than "warming" in TCM frameworks), Panax notoginseng (Chinese pseudoginseng, San Qi, with distinct uses in cardiovascular and hemorrhage contexts), Panax japonicus (Japanese ginseng), and several other less commercially significant species. The Panax ginseng commercial supply is dominated by Korea, where Korean Red Ginseng (KRG), produced by steaming and drying fresh ginseng root, has both regulatory recognition as functional food and substantial cultural-economic prominence. White ginseng (sun-dried without steaming) and red ginseng have different ginsenoside profiles: steam processing converts some ginsenosides to different forms (Rg3, Rh1, Rh2, and others) that have distinct pharmacological properties. The active compound class is ginsenosides, triterpene saponins with a four-ring dammarane structure and various sugar attachments. Over 40 ginsenosides have been characterized; the most clinically relevant include Rb1, Rb2, Rc, Rd (the "protopanaxadiol" or PPD group) and Rg1, Re, Rf (the "protopanaxatriol" or PPT group). Different ginsenosides have substantially different, sometimes opposing, pharmacological effects: Rg1 is generally stimulating and supports CNS function while Rb1 is more sedating and supports anti-inflammatory effects. The relative composition (PPT:PPD ratio) determines the overall pharmacological profile, providing one explanation for the historical "warming vs cooling" distinctions between different Panax species and preparations. Standardized commercial extracts typically specify 4-7% total ginsenosides; the KSM-66 analog branding (KGC Cheong Kwan Jang from Korea Ginseng Corporation) provides the highest commercial standardization in the category. The mechanism of action involves multiple pathways: nitric oxide pathway support (relevant to erectile function evidence), HPA axis modulation in stress contexts, mild estrogen receptor binding (relevant to hormone-sensitive cancer caution), AMPK activation supporting energy metabolism, modest CYP450 modulation (less than schisandra), and immune cytokine effects. The Cheong Kwan Jang Korean Red Ginseng inheritance carries substantial Korean clinical research evidence; modern Western RCTs (Reay 2005 cognitive, Hong 2002 erectile function, Barton 2013 cancer fatigue at Mayo Clinic) provide additional evidence base. Effect sizes are consistently modest versus pharmaceutical alternatives but the evidence breadth across multiple applications and substantial cultural-clinical inheritance distinguish Panax ginseng among adaptogens.
How it is taken
Standard Panax ginseng dosing centers on 200-1000mg/day of standardized extract (4-7% total ginsenosides) for general adaptogenic and cognitive applications. Korean Red Ginseng (Cheong Kwan Jang and similar premium KRG) is typically dosed at 1-3g/day of extract or whole root, higher gram weights but lower ginsenoside concentration than standardized extracts at equivalent total ginsenoside delivery. For specific clinical applications: erectile dysfunction (Hong 2002 protocol) uses 1.8-3g/day Korean Red Ginseng for 8+ weeks; cognitive performance studies use 200-400mg standardized extract acutely or chronically; cancer-related fatigue (Barton 2013) uses 2g/day American ginseng (Wisconsin) under oncology supervision. Take with or without food, absorption is acceptable either way, though some users prefer with food to reduce minor GI sensitivity. Take in the morning or early afternoon, the stimulating effects can interfere with sleep if taken late in the day. The Korean traditional use cycle pattern often involves 2-3 month cycles with 1-month breaks; modern Western trials typically use continuous dosing for 8-12 weeks without breaks. Higher doses (>3g/day standardized extract) produce diminishing returns and may increase side effects (sleep disruption, headache, GI upset). The species and preparation matter substantially: Korean Red Ginseng has different ginsenoside profile than white ginseng or American ginseng, with different clinical effect profiles. The "all-healing" panacea framing in commercial marketing exceeds what current evidence supports, modest effects across multiple applications is the realistic evidence-based positioning. Athletic competition users should verify NSF Certified for Sport or Informed Sport testing given historical contamination concerns and quality variation.
- Standardized extract
- 200-1000mg/day (4-7% ginsenosides)
- Korean Red Ginseng (whole or extract)
- 1-3g/day
- Erectile dysfunction (Hong 2002)
- 1.8-3g/day KRG, 8+ weeks
- Cognitive (Reay protocols)
- 200-400mg standardized extract
- Cancer-related fatigue (Barton 2013)
- 2g/day American ginseng
- Diabetes glycemic adjunct
- 200-2000mg/day
- Timing
- Morning or early afternoon
- Korean traditional cycles
- 2-3 months on, 1 month off
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Korean Red Ginseng (KRG, Cheong Kwan Jang)
The Korea Ginseng Corporation (KGC) "Cheong Kwan Jang" brand is the dominant premium Korean Red Ginseng product globally, produced from 6-year-old ginseng roots, steamed and dried using established Korean processing methods. Regulated as functional food in Korea with substantial regulatory and quality oversight. Used in essentially all modern Korean Red Ginseng clinical trials including the major Korean cognitive and erectile function studies. Premium pricing reflects clinical inheritance and quality control. Acceptable for high-end Western supplementation.
Standardized Panax Ginseng Extract (4-7% Ginsenosides)
Generic standardized extracts specifying 4-7% total ginsenosides content. Major reputable manufacturers (Solgar, Thorne, NOW Foods, Pure Encapsulations, Nature's Way) provide reliable composition at substantially lower cost than Cheong Kwan Jang KRG. Acceptable for most users; clinical trial inheritance technically belongs to specific extract preparations but standardized composition produces equivalent effects.
White Ginseng (Sun-Dried, Unsteamed)
Traditional Korean and Chinese preparation, fresh ginseng root sun-dried without the steaming process. Different ginsenoside profile from red ginseng, more original ginsenoside content, less Rg3 and Rh family compounds. Considered "less warming" in TCM frameworks than red ginseng. Reasonable traditional form; less commercial standardization than red ginseng.
American Ginseng (Panax quinquefolius)
Different species, native to eastern North America. Distinct ginsenoside profile (higher Rb1, lower Rg1) producing more "cooling" effects in TCM frameworks. Used in Barton 2013 Mayo Clinic cancer-related fatigue trial (2g/day Wisconsin Ginseng). Reasonable alternative to Panax ginseng particularly for cancer fatigue indication.
Ginseng Tea (Tincture, Traditional Preparation)
Traditional preparation form, decoction of ginseng root in hot water, sometimes with other herbs. Lower active compound concentration per serving than concentrated extracts. Reasonable for traditional use; less reliable for clinical-grade applications.
Korean Ginseng Slices / Whole Root
Whole or sliced dried ginseng root for chewing, decoction, or food preparation. Traditional Korean consumption form, often consumed during winter for warming and immune support. Active compound content varies based on age of root and processing.
Ginseng + Multi-Adaptogen Combinations
Multi-adaptogen formulations combining Panax ginseng with eleuthero, rhodiola, ashwagandha, or other adaptogens. Mechanistically reasonable for users seeking broader adaptogenic support; individual ginseng dose is often sub-therapeutic. Verify ginseng dose specifically rather than relying on category positioning.
Generic / Substituted Ginseng Products
Substantial adulteration history in commercial supply, substitution with other Panax species (P. notoginseng, P. quinquefolius substituted for P. ginseng or vice versa), substitution with unrelated plants (mandrake root historically), and low-quality wild harvest from non-Panax species. The "ginseng" category includes substantial quality variation; species verification matters substantially for clinical effects.
Who it works for, and who it does not
Erectile dysfunction (mild to moderate)
Hong 2002 Korean RCT and substantial subsequent evidence support Korean Red Ginseng 1.8-3g/day for mild-to-moderate erectile function improvements. Effect sizes substantially smaller than PDE5 inhibitors (sildenafil, tadalafil); reasonable for users preferring non-pharmaceutical approach or as adjunct to PDE5 inhibitors. Not substitute for established ED treatment in severe cases.
Cognitive performance (acute and chronic)
Kennedy 2002, Reay 2005/2010, Scholey 2010 support both acute (1-2 hours post-dose) and chronic (weeks) cognitive performance effects. Effect sizes modest; particularly relevant for working memory, attention, and mental performance under fatigue. Reasonable for cognitively-demanding contexts.
Cancer-related fatigue (American ginseng particularly)
Barton 2013 Mayo Clinic RCT of 2g/day Wisconsin Ginseng (American, P. quinquefolius) in cancer-related fatigue: significant fatigue improvements at 8 weeks. Foundational oncology adjunctive evidence. Coordinate with oncology, interactions with chemotherapy agents possible.
Type 2 diabetes (glycemic adjunct)
Sotaniemi 1995 and subsequent trials support modest glycemic improvements at 200-2000mg/day. Effect sizes smaller than metformin or other established diabetes medications; reasonable adjunct to standard diabetes management. Monitor glucose when initiating; coordinate with endocrinology for established diabetes management.
Immune support / cold prevention
Multiple Korean clinical trials support immune cell activity improvements and modest cold/flu prevention. Particularly studied in older adults and during high-stress periods (exam stress, athletic training cycles). Reasonable component of comprehensive immune support during high-risk periods.
Stress-related fatigue and general adaptogenic use
Soviet research tradition and Korean traditional inheritance both support general adaptogenic use for stress-related fatigue. Effect sizes consistently modest; reasonable component of comprehensive stress management.
Older adults (cognitive function, fatigue)
Korean traditional use and modern research support broader use in older adult populations for cognitive function, energy support, and immune function. Reasonable component of healthy aging protocols.
Hormone-sensitive cancers
Mild estrogen receptor binding activity warrants caution in users with breast cancer, ovarian cancer, endometrial cancer, or other hormone-sensitive conditions. Specialist coordination through oncology. The American ginseng (Wisconsin) used in Barton 2013 cancer fatigue trial was specifically permitted in that protocol but generalization to all hormone-sensitive cancers is not appropriate without specialist guidance.
Warfarin users
Documented case reports of INR variation (both decreased and increased) with Panax ginseng-warfarin combination. Coordinate with prescribing physician; monitor INR if initiating ginseng on stable warfarin therapy.
Pregnancy and lactation
Limited safety data in pregnancy; some traditional Asian medicine guidance suggests caution. Generally avoid by precautionary principle without OB-GYN coordination.
Hypertension (uncontrolled)
Mild stimulant-like effects and complex cardiovascular pharmacology produce mixed effects on blood pressure. Russian and Korean clinical guidance has historically suggested caution in uncontrolled hypertension; modern evidence is mixed. Monitor BP when initiating in users with cardiovascular conditions.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
PDE5 Inhibitors (Sildenafil, Tadalafil)
Both support erectile function through different mechanisms, Panax ginseng through NO pathway support and possibly central effects; PDE5 inhibitors through direct phosphodiesterase inhibition. Combined use is generally well-tolerated but theoretical additive hypotension warrants moderate caution. Coordinate with prescribing physician for combined ED management.
Warfarin
Documented INR variation case reports (both decreased and increased). Coordinate with prescribing physician; monitor INR if initiating ginseng on stable warfarin therapy. Among the more clinically significant supplement-anticoagulant interactions to monitor.
Diabetes Medications
Additive glucose-lowering effects. Monitor blood glucose when initiating; coordinate with endocrinology in established diabetes management. The glycemic effects can produce clinically meaningful glucose drops in users on multiple diabetes medications.
MAO Inhibitors (Phenelzine, Selegiline)
Mild MAO inhibitory activity in some ginsenosides creates theoretical interactions with pharmaceutical MAO inhibitors. Generally avoid combined use; coordinate with psychiatry if both clinically necessary.
Estrogenic Medications and Hormone Therapy
Mild estrogen receptor binding activity may interact with estrogenic medications, oral contraceptives, hormone replacement therapy, and selective estrogen receptor modulators. Coordinate with prescribing physician for users on hormonal therapy.
Hormone-Sensitive Cancers (Breast, Ovarian, Endometrial)
Mild estrogenic activity warrants caution in hormone-sensitive cancers. Coordinate with oncology before initiating in users with current or history of hormone-sensitive cancers. Specific exceptions (Barton 2013 cancer fatigue trial) involved specific protocols and species (American ginseng).
Stimulants (Caffeine, ADHD Medications)
Additive stimulant-like effects. Monitor for jitteriness, anxiety, sleep disruption. Reasonable combination for many users but worth monitoring response.
Rhodiola and Other Adaptogens
Common combination in adaptogen formulations. Different mechanisms; mechanistically complementary for broader stress and fatigue support. Verify individual product doses rather than relying on category positioning.
Pre-Surgery
Antiplatelet activity and blood pressure effects warrant 2-week discontinuation before elective surgery as conservative practice. Coordinate with anesthesiology.
What to look for on the label
Look for: explicit Panax ginseng species specification (or Panax quinquefolius for American); Korean Red Ginseng (KRG) source specification for premium products; standardization to specific ginsenoside content (typically 4-7% total ginsenosides); Cheong Kwan Jang branding for premium Korean Red Ginseng; root age specification (6-year-old roots for premium KRG); NSF or USP third-party verification; reputable manufacturer with quality control disclosure. Avoid: products labeled only "ginseng" without species specification (likely contain substituted material or low-quality material); products at unusually low cost (likely indicates substitution or low quality); products from manufacturers without quality verification disclosure; combination products that obscure individual ginseng dose. The species substitution and adulteration concern is substantial in this category.
Safety in detail
- Generally well-tolerated at standard doses in healthy users. Substantial Korean and Chinese clinical use over centuries supports broad safety profile.
- Mild stimulant-like effects can produce sleep disruption if taken in afternoon or evening. Morning or early afternoon dosing is standard.
- Headache, jitteriness, palpitations, and elevated blood pressure can occur at higher doses or in sensitive users.
- GI upset (mild nausea, abdominal discomfort) is the most common side effect; typically dose-related and resolves with dose reduction or food.
- Warfarin interaction (INR variation) is among the most clinically significant supplement interactions to monitor. Documented case reports support coordination with anticoagulation management.
- Hormone-sensitive cancer caution, mild estrogenic activity warrants oncology coordination in users with current or history of breast cancer, ovarian cancer, endometrial cancer.
- Hypoglycemia risk in users on diabetes medications. Monitor blood glucose; coordinate with endocrinology.
- Pregnancy and lactation: limited systematic safety data; avoid by precautionary principle. Some traditional Asian medicine guidance suggests caution.
- Pediatric use: limited safety data; not routinely recommended in pediatric populations.
- Theoretical mania risk in bipolar disorder due to mild stimulating effects. Coordinate with psychiatry in bipolar disorder.
- Adulteration concern is substantial, historical mandrake substitution, Panax notoginseng substitution, low-quality wild harvest material. Quality verification matters substantially.
- Long-term safety profile in healthy users at standard doses is excellent across millennia of Korean traditional use and modern clinical research.
What people get wrong
Often saidAll ginseng is the same.
ActuallyIt is not. Panax ginseng (Asian), Panax quinquefolius (American), Panax notoginseng (Chinese pseudoginseng), Panax japonicus, and other species have substantially different ginsenoside profiles and clinical effects. Eleutherococcus senticosus ("Siberian ginseng") is not even in the Panax genus. Species verification matters substantially.
Often saidKorean Red Ginseng is the same as white ginseng.
ActuallyThey are not. Steam processing (red ginseng) converts some ginsenosides to different forms (Rg3, Rh1, Rh2 family) producing different pharmacological profiles. Korean Red Ginseng has substantial Korean clinical evidence; white ginseng has different evidence base.
Often saidGinseng cures erectile dysfunction.
ActuallyIt does not cure ED. The Hong 2002 evidence supports modest erectile function improvements in mild-to-moderate ED, substantially smaller effects than PDE5 inhibitors. Reasonable for mild ED; not substitute for established ED treatment in severe cases.
Often saidPanax ginseng is "all-healing" as the Greek name suggests.
ActuallyThe Greek name reflects Western perception of Asian traditional medicine claims rather than current scientific evidence. Modern clinical evidence supports modest effects across multiple applications (cognitive, erectile, immune, glycemic, fatigue), not the dramatic all-healing claims of traditional positioning.
Often saidHigher ginseng doses produce proportionally better results.
ActuallyDiminishing returns set in above 3g/day standardized extract. The dose-response curve flattens; higher doses primarily produce more side effects (sleep disruption, headache, palpitations).
Often saidGinseng has no drug interactions.
ActuallyWarfarin INR variation is documented in case reports. Diabetes medications produce additive glucose-lowering. Hormone-sensitive cancer caution warranted. Coordinate with prescribing physician for combined use with anticoagulants, diabetes medications, or hormonal therapy.
Often saidAnyone can take Korean Red Ginseng safely.
ActuallyPregnancy, hormone-sensitive cancers, uncontrolled hypertension, bipolar disorder, and warfarin therapy all warrant specialist coordination. The "safe natural supplement" framing should acknowledge these specific contraindication and caution contexts.
Who profits, and who pushes back
Mainstream sexual medicine
The Panax ginseng erectile function effects (Hong 2002 and subsequent) are real but modest, substantially smaller than PDE5 inhibitors (sildenafil, tadalafil, vardenafil) which produce reliable clinical effects in most patients. Reasonable for users preferring non-pharmaceutical approach in mild ED; not substitute for established ED treatment in severe cases. The "natural alternative to Viagra" marketing exceeds what the actual effect-size evidence supports.
Mainstream oncology and hormone-sensitive cancer guidance
The mild estrogenic activity of ginsenosides warrants caution in users with current or history of hormone-sensitive cancers (breast, ovarian, endometrial). Mainstream oncology guidance generally suggests coordination with treating physician before initiating Panax ginseng in these populations. The Barton 2013 American ginseng cancer fatigue evidence was in mixed cancer populations with specific oncology protocol; generalization to all cancer survivors is not appropriate without specialist guidance.
Israel I. Brekhman
Foundational Soviet pharmacologist who included Panax ginseng in the adaptogen research program alongside eleuthero and schisandra. Foundational scientific contribution.
Andrew Scholey
Leading modern researcher on cognitive supplement effects, including Panax ginseng acute and chronic cognitive trials. Independent academic with disclosed industry collaborations.
David Kennedy / Mark Wesnes
Northumbria University research group that conducted foundational cognitive performance trials of Panax ginseng. Independent academic with disclosed industry collaborations.
Korean Red Ginseng research consortium
Substantial Korean academic research consortium publishing Korean Red Ginseng clinical trials. Some Korea Ginseng Corporation industry collaboration disclosed in specific studies.
Korea Ginseng Corporation (KGC) / Cheong Kwan Jang
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Korean state-affiliated dominant Korean Red Ginseng manufacturer and brand. Substantial commercial interest in Korean Red Ginseng evidence. Disclosed industry source for Korean Red Ginseng research.
Mayo Clinic Cancer Center
Conducted Barton 2013 cancer-related fatigue trial of Wisconsin American Ginseng. Independent academic cancer center. Important Western academic medical center contribution to oncology supplement evidence.
Where the research comes from
| Place | Share of published research |
|---|---|
| Korea | 38% |
| China | 26% |
| North America | 14% |
| Japan | 12% |
| Other | 10% |
Research published from: Korea · China.
How we got here
Panax ginseng has been cultivated in Korea, China, and Russia for more than two thousand years, among the longest continuous medicinal plant uses in any tradition. Chinese traditional medicine (TCM) developed elaborate frameworks for ginseng use across multiple species (Ren Shen for Panax ginseng, Xi Yang Shen for Panax quinquefolius American, San Qi for Panax notoginseng), with distinct indications and "energetic" properties (warming, neutral, cooling) for different species and preparations. The "all-healing" framing in Chinese tradition is captured in the genus name Panax (from Greek panakeia, "all-healing") that Carl Linnaeus assigned when formally classifying the genus in 1753, reflecting Western awareness of the Asian medicinal reputation. Korean ginseng cultivation has substantial cultural and economic prominence. The Goryeo dynasty (918-1392) institutionalized ginseng cultivation as state monopoly; the Joseon dynasty (1392-1910) developed Korean Red Ginseng processing methods that remain largely unchanged today. Korean Red Ginseng has been Korea's most prominent traditional export and remains a major Korean cultural-economic asset. Korea Ginseng Corporation (KGC), the state-affiliated Cheong Kwan Jang brand operator, holds substantial Korean market position and exports globally. The Soviet scientific era brought Panax ginseng into modern pharmacological framework. The Brekhman/Dardymov 1969 adaptogen framework included Panax ginseng as foundational compound alongside Eleutherococcus and Schisandra. Soviet research applications included athletic performance, military operational performance, and cosmonaut performance support. The modern Western scientific era developed substantially through the 1990s-2000s. Korean clinical research consortia conducted substantial trials in Korean populations on erectile function (Hong 2002, Kim 1998), immune function, cognitive performance, and various other applications. Western pharmaceutical research (Northumbria University Kennedy/Reay cognitive trials 2002-2010, Mayo Clinic Barton 2013 cancer fatigue trial, others) extended the evidence base into modern Western RCT methodology. The American ginseng commercial industry developed substantially differently, Wisconsin became the dominant American ginseng cultivation region by the late 19th century, with American ginseng historically exported to Asia where its "cooling" properties were valued. The Barton 2013 Mayo Clinic cancer fatigue trial specifically used Wisconsin Ginseng (American ginseng), distinguishing it from Korean Red Ginseng clinical inheritance. The modern consumer market has seen substantial premium positioning of Cheong Kwan Jang Korean Red Ginseng globally, alongside generic standardized Panax ginseng extracts at lower cost. The species verification and adulteration concern persists, multiple Panax species substitution and historical mandrake adulteration documented historically continues to affect lower-quality commercial supply. The Yoon 2014 Korean prospective cohort study extending Korean ginseng longevity associations and continued Korean clinical research consortium output through the 2010s-2020s has maintained the Panax ginseng evidence base. Integration with modern Western pharmacology, established hormone-sensitive cancer concerns, and increasingly rigorous quality verification continue to refine the modern ginseng evidence framework.
- ~2000 BCEKorean and Chinese ginseng cultivation begins (continuous to present)
- 918-1392Goryeo dynasty institutionalizes Korean ginseng cultivation
- 1392-1910Joseon dynasty develops Korean Red Ginseng processing methods
- 1753Linnaeus formally classifies Panax genus (Greek panakeia, "all-healing")
- Late 19th centuryWisconsin American ginseng cultivation industry develops
- 1950s-1980sSoviet pharmacological research includes Panax ginseng (Brekhman)
- 1969Brekhman and Dardymov adaptogen framework
- 1995Sotaniemi diabetes trial
- 1998Kim Korean Red Ginseng erectile dysfunction trial
- 2002Hong KRG ED trial; Kennedy cognitive performance
- 2005-2010Reay Northumbria cognitive trials
- 2010Scholey Australian cognitive trial
- 2013Barton Mayo Clinic American ginseng cancer fatigue trial
- 2014Yoon Korean prospective longevity cohort
- 2010s-2020sKorea Ginseng Corporation clinical research consortium expansion
What we do not know
- Whether the Korean Red Ginseng clinical inheritance translates to non-Korean populations at equivalent effect sizes, substantial clinical research is Korean-based.
- Whether the steamed (red) versus sun-dried (white) ginseng distinction produces clinically meaningful differences in modern Western supplement contexts.
- Whether American ginseng (P. quinquefolius) and Asian ginseng (P. ginseng) have meaningfully different cancer fatigue effects, Barton 2013 used American specifically.
- How best to address the species substitution and adulteration market, DNA-based authentication has become cost-effective but consumer market verification remains inconsistent.
- Whether the "all-healing" panacea positioning will resolve into specific evidence-based applications or persist as overstated marketing.
- Whether ginseng has applications in heart failure or other cardiovascular conditions beyond the modest evidence in general adaptogenic and metabolic contexts.
- Whether the Yoon 2014 longevity association in Korean prospective cohort study reflects causal relationships or healthy-user confounding.
- How best to integrate ginseng with established stress management, sexual medicine, and cognitive enhancement interventions in modern integrative practice.
Legal status
Universally available globally as dietary supplement. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Korean Red Ginseng is regulated as functional food in Korea with substantial regulatory and quality oversight; Korea Ginseng Corporation's Cheong Kwan Jang holds dominant Korean market position. Major Western retail brands include Cheong Kwan Jang (Korean import), Nature's Way, NOW Foods, Solgar, Thorne, Pure Encapsulations, and many adaptogen-focused supplement manufacturers. American ginseng products (Wisconsin Ginseng, Ginseng Board of Wisconsin) provide alternative species with Barton 2013 Mayo Clinic clinical inheritance. Traditional Chinese medicine practices use Panax ginseng (Ren Shen) in established formulations. Production is concentrated in Korea (Korean Red Ginseng), China (multiple Panax species), Wisconsin (American ginseng), and other regions. The Korean Red Ginseng category specifically has substantial premium positioning supported by Korea Ginseng Corporation's industry-leading quality control and clinical research investment. Adulteration and species substitution concerns persist in lower-quality commercial supply.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Panax ginseng sourcing is dominated by Korean cultivation (particularly Geumsan and Punggi regions famous for ginseng), Chinese cultivation in Northeast provinces, Russian cultivation in the Far East, and (for American ginseng specifically) Wisconsin cultivation in the United States. Korean Red Ginseng production involves specific processing, 6-year-old ginseng roots are steamed and dried using established Korean methods that produce the characteristic red color and modified ginsenoside profile. Korea Ginseng Corporation's Cheong Kwan Jang maintains the most rigorous Korean Red Ginseng quality control globally. White ginseng production uses 4-6-year-old roots sun-dried without steaming. American ginseng cultivation in Wisconsin (Ginseng Board of Wisconsin) produces the predominant North American supply. Quality variation across brands is substantial, species verification through DNA authentication, HPLC ginsenoside profiling, and macroscopic botanical authentication addresses persistent substitution concerns. The "ginseng" category includes products that may contain other Panax species, unrelated plants (historical mandrake substitution), or low-quality wild harvest material. Reputable manufacturers with rigorous quality verification address these concerns; third-party testing (NSF, USP, Informed Sport) provides additional quality assurance.
At a glance
- Species
- Panax ginseng (Korean/Asian ginseng)
- Family
- Araliaceae (same family as Eleutherococcus, different genus)
- Active compounds
- Ginsenosides (Rb1, Rg1, Re, Rb2, Rd, Rc, others, 40+ characterized)
- Standardization
- 4-7% total ginsenosides typical
- Standard daily dosing
- 200-1000mg standardized extract
- Korean Red Ginseng dosing
- 1-3g/day
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Panax Ginseng. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
Cochrane review of 9 RCTs (587 men) found only a trivial, low-certainty effect on the IIEF-15 erectile-function domain (MD 3.52, 95% CI 1.79 to 5.25), most trials from South Korea
Lee HW, Lee MS, Kim TH, et al. Ginseng for Erectile Dysfunction: A Cochrane Systematic Review (PMC)
Same Cochrane review, PubMed record
16-RCT, 770-participant meta-analysis: modest fasting-glucose reduction (MD -0.31 mmol/L) but no HbA1c or insulin effect, I-squared 89 percent, funnel-plot asymmetry suggesting bias
Shishtar E, et al. The Effect of Ginseng on Glycemic Control, PLoS One 2014 (PMC)
Same glycemic meta-analysis, PLoS One primary article
Systematic review pooling 8 fatigue RCTs (678 participants): ginseng superior to placebo on clinical effect (OR 1.31, 95% CI 1.17 to 1.46), risk-of-bias 4 to 7 of 7, publication bias on some markers; Rg1/Rb1/Re mechanisms
Ginsenosides reduce warfarin anticoagulation and lower INR via CYP2C9/CYP3A4 induction and clotting-factor restoration; deregulation of ginseng as food is flagged as a safety hazard for warfarin patients
Randomized study in ischemic-stroke patients found no significant INR change with co-administered Panax ginseng over two weeks, showing the interaction evidence is not unanimous
Frontiers full-text of the fatigue systematic review, corroborating pooled clinical effect and mechanistic notes
Frontiers in Pharmacology, fatigue systematic review full text
DARE quality-assessed record of the glycemic meta-analysis, independent indexing of methods and conclusion
The studies that matter
Brekhman foundational Panax research1960s-80s
Soviet pharmacological research at the Institute of Biologically Active Substances included Panax ginseng alongside eleuthero and schisandra. The Brekhman/Dardymov 1969 adaptogen framework included Panax ginseng as a founding compound. Foundational Soviet inheritance.
Sotaniemi diabetes trialDiabetes Care 1995
Finnish RCT of Panax ginseng in type 2 diabetes: modest improvements in fasting glucose, HbA1c, and physical performance over 8 weeks. Foundational diabetes glycemic adjunct evidence.
Kim erectile dysfunction trialJ Urol 1998
Korean RCT of Korean Red Ginseng in erectile dysfunction: 1.8g/day produced modest erectile function improvements versus placebo. Foundational Korean clinical evidence for ED application.
Hong erectile dysfunction trialJ Urol 2002
Korean RCT comparing Korean Red Ginseng to placebo in patients with mild-to-moderate ED: significant improvements in erectile function over 8 weeks. Among the most-cited erectile function evidence in the supplement category.
Kennedy cognitive performancePharmacol Biochem Behav 2002
UK trial demonstrating acute cognitive enhancement effects of Panax ginseng on working memory and mental performance in healthy young adults. Foundational acute cognitive evidence.
Reay glucose-cognition interactionHum Psychopharmacol 2005
UK trial demonstrating Panax ginseng acute cognitive effects with glucose interaction in young healthy adults. Continued Northumbria group cognitive research tradition.
Reay long-term cognitive trialJ Psychopharmacol 2010
UK trial of chronic Panax ginseng supplementation in healthy young adults: modest improvements in working memory and cognitive performance. Extended the acute cognitive evidence to chronic supplementation.
Scholey cognitive performancePsychopharmacology 2010
Australian RCT extending cognitive performance evidence base in healthy adults. Continued modern Western RCT tradition.
Barton Mayo Clinic cancer-related fatigueJ Natl Cancer Inst 2013
Mayo Clinic RCT of 2g/day Wisconsin (American) ginseng in patients with cancer-related fatigue: significant fatigue improvements at 8 weeks. Foundational oncology adjunctive evidence, note this was American ginseng (P. quinquefolius), not Korean.
Cheong Kwan Jang Korean Red Ginseng research consortiumKorea Ginseng Corporation, 2010s-2020s
Substantial Korean clinical research consortium publishing in Korean and international journals on Korean Red Ginseng applications in immune function, cognitive performance, energy metabolism, and various conditions. Industry-supported but substantial methodological quality. Korea Ginseng Corporation (KGC) holds dominant Korean market position.
Yoon longevity Korean prospectiveJ Ginseng Res 2014
Korean prospective cohort study of ginseng consumption and all-cause mortality: associations between long-term Korean Red Ginseng consumption and reduced mortality risk. Observational evidence supporting longevity positioning in Korean clinical context.